Homepage
Author:
Orchestra BioMed Holdings, Inc.
Posted Date:
May 12, 2026
Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
Orchestra BioMed Holdings, Inc.
May 12, 2026
Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027
Orchestra BioMed Holdings, Inc.
May 12, 2026
Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement
Orchestra BioMed Holdings, Inc.
May 6, 2026
Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement
Orchestra BioMed Holdings, Inc.
May 6, 2026
FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy
Orchestra BioMed Holdings, Inc.
April 30, 2026
Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026
Orchestra BioMed Holdings, Inc.
April 23, 2026
Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
Orchestra BioMed Holdings, Inc.
March 12, 2026
Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT
Orchestra BioMed Holdings, Inc.
March 3, 2026
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
Orchestra BioMed Holdings, Inc.
February 19, 2026
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Orchestra BioMed Holdings, Inc.
February 13, 2026
